RCUS Q2 2025 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RCUSArcus Biosciences, Inc.

$2B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$160M+310.3% YoY

Gross Profit

$160M100.0% margin

Operating Income

-$8M-5.0% margin

Net Income

-$8M-5.0% margin

EPS (Diluted)

$0.04

QoQ Revenue Growth

+471.4%

Cash Flow

Operating Cash Flow

-$133M

Free Cash Flow

-$133M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$526M

Stockholders' Equity

$549M

Cash & Equivalents

$248M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$160M	$39M	+310.3%
Gross Profit	$160M	$39M	+310.3%
Operating Income	-$8M	-$106M	+92.5%
Net Income	-$8M	-$93M	+91.4%

Revenue Segments

License And R&D Services

$192M92%

R&D Services

$17M8%